Direct comparison of mavacamten versus placebo and aficamten versus placebo; and indirect comparison of aficamten versus mavacamten through a common comparator placebo.
| Direct evidence | ||||
|---|---|---|---|---|
| Outcome | Drug 1 | Drug 2 | No. of studies | Pooled effect sizeMD [95% CI] |
| Change in resting LVOT gradient | Aficamten | Placebo | 2 | –48.32 [–57.48; –39.17] |
| Mavacamten | Placebo | 3 | –63.07 [–70.40; –55.74] | |
| Decrease in LVEF | Aficamten | Placebo | 2 | –8.47 [–12.41; –4.52] |
| Mavacamten | Placebo | 4 | –2.88 [–5.69; –0.06] | |
| NYHA class improvement | Aficamten | Placebo | 2 | 2.12 [0.95; 3.28] |
| Mavacamten | Placebo | 4 | 2.48 [1.66; 3.30] | |
| Indirect evidence | ||||
| Outcome | Drug 1 | Drug 2 | Pooled effect size MD [95%CI] | Inconsistency tests (between designs)Q, df |
| Change in resting LVOT gradient | Aficamten | Mavacamten | 14.74 [3.02; 26.47] | 0.00 |
| Decrease in LVEF | Aficamten | Mavacamten | –5.59 [–10.43; –0.75] | 0.00 |
| NYHA class improvement | Aficamten | Mavacamten | –0.37 [–1.79; 1.06] | 0.00 |
MD: mean difference; LVOT: left ventricular outflow tract; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.
The supplementary tables and figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/101289_sup_1.pdf.
Pre-print: the pre-print is posted on SSRN: http://dx.doi.org/10.2139/ssrn.5183557. Conference: the abstract of this manuscript was presented to the conference at the APPNA Spring Meeting 2025 and is published in the conference proceedings in Pakistan Heart Journal under the doi: https://pakheartjournal.com/index.php/pk/article/view/3065.
Ayesha A: Writing—original draft, Supervision, Software, Methodology, Formal analysis, Data curation, Conceptualization. BA: Data curation, Methodology, Formal analysis, Writing—original draft. Arfa A: Data curation, Visualization, Formal analysis, Software, Writing—original draft. MM: Methodology, Software, Writing—original draft. ET: Visualization, Software, Methodology, Writing—original draft. AH: Formal analysis, Software, Writing—review & editing. MZB: Writing—original draft, Methodology, Writing—review & editing. Aleena A: Writing—review & editing, Formal analysis, Visualization. SA: Writing—original draft, Software, Visualization. MWZK: Writing—review & editing, Writing—original draft. All authors have read and approved the submitted version of this manuscript.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
All the data utilized in this study are available in the relevant figures and Tables S3–5.
This research did not receive any specific grant or funding from funding agencies in the public, commercial, or not-for-profit sectors.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.